uproleselan

Also Known As:

(2S)-2-(((2R,3R,4R,5R,6R)-3-acetamido-2-(((1R,2R,3S,5R)-5-((2-(4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxaoctatriacontanamido)ethyl)carbamoyl)-3-ethyl-2-(alpha-L-galactopyranosyloxy)cyclohexyl)oxy)-5-hydroxy-6-(hydroxymethyl)oxan-4-yl)oxy)-3-cyc; ABI-701; ABI701; GMI-1271; GMI-1271 free acid; GMI-1271 sodium; GMI-1687; Sodium (2S)-2-(((2R,3R,4R,5R,6R)-3-acetamido-2-(((1R,2R,3S,5R)-5-((2-(4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxaoctatriacontanamido)ethyl)carbamoyl)-3-ethyl-2-(alpha-L-galactopyranosyloxy)cyclohexyl)oxy)-5-hydroxy-6-(hydroxymethyl)oxan-4-yl)oxy; uproleselan sodium

Networked: 8 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Magnani, John L: 4 articles (01/2022 - 01/2017)
2.	Hawley, Angela: 3 articles (01/2022 - 01/2020)
3.	Myers, Daniel D: 3 articles (01/2022 - 01/2017)
4.	Sood, Suman: 3 articles (01/2022 - 01/2017)
5.	Adili, Reheman: 2 articles (01/2022 - 01/2020)
6.	Crego, Kiley: 2 articles (01/2022 - 01/2020)
7.	Dunivant, Veronica: 2 articles (01/2022 - 01/2020)
8.	Durham, Laura: 2 articles (01/2022 - 01/2020)
9.	Holinstat, Michael: 2 articles (01/2022 - 01/2020)
10.	Lester, Patrick: 2 articles (01/2022 - 01/2020)

Related Diseases

1.	Mucositis 01/01/2022 - "The addition of uproleselan to chemotherapy was well tolerated, with high remission rates, low induction mortality, and low rates of mucositis, providing a strong rationale for phase 3 randomized confirmatory studies. " 01/18/2021 - "Several preclinical and clinical studies summarized herein demonstrate that uproleselan has favorable safety and pharmacokinetics and is a tumor microenvironment-disrupting agent that improves the efficacy of chemotherapy, reduces side effects such as neutropenia, intestinal mucositis and infections, and extends overall survival. "
2.	Neutropenia 01/18/2021 - "Several preclinical and clinical studies summarized herein demonstrate that uproleselan has favorable safety and pharmacokinetics and is a tumor microenvironment-disrupting agent that improves the efficacy of chemotherapy, reduces side effects such as neutropenia, intestinal mucositis and infections, and extends overall survival. "
3.	Infections 01/18/2021 - "Several preclinical and clinical studies summarized herein demonstrate that uproleselan has favorable safety and pharmacokinetics and is a tumor microenvironment-disrupting agent that improves the efficacy of chemotherapy, reduces side effects such as neutropenia, intestinal mucositis and infections, and extends overall survival. "
4.	Hemorrhage 02/01/2020 - "GMI-1271, a potent small-molecule E-selectin antagonist, has been shown in mouse models to decrease thrombus burden with a low risk of bleeding. " 01/01/2017 - "E-selectin inhibition with GMI-1271 decreases venous thrombosis without profoundly affecting tail vein bleeding in a mouse model." 01/01/2022 - "This study evaluated E-selectin inhibition with GMI-1271 (Uproleselan [GMI]) alone and in combination with the standard of care low-molecular-weight heparin (LMWH) to improve vein recanalization, decrease vein wall inflammation and protect against adverse bleeding in a primate model. "
5.	Inflammation (Inflammations) 01/01/2020 - "GMI-1271 significantly decreased vein wall inflammation by MRV with gadolinium vein wall enhancement vs control also on day 14 (P < .0001) and day 21 (P < .0001). " 01/01/2022 - "This study evaluated E-selectin inhibition with GMI-1271 (Uproleselan [GMI]) alone and in combination with the standard of care low-molecular-weight heparin (LMWH) to improve vein recanalization, decrease vein wall inflammation and protect against adverse bleeding in a primate model. "

Related Drugs and Biologics

1.	uproleselan
2.	E-Selectin
3.	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
4.	Mitoxantrone (Novantrone)
5.	Etoposide (VP 16)
6.	Cytarabine (Cytosar-U)
7.	Enoxaparin (Lovenox)
8.	Cell Adhesion Molecules
9.	Gadolinium
10.	Imatinib Mesylate (Gleevec)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)